『Lepodisiran and the Emerging Role of Oxidized Phospholipids in Lipoprotein(a) Risk』のカバーアート

Lepodisiran and the Emerging Role of Oxidized Phospholipids in Lipoprotein(a) Risk

Lepodisiran and the Emerging Role of Oxidized Phospholipids in Lipoprotein(a) Risk

無料で聴く

ポッドキャストの詳細を見る

プレミアムプランが3か月 月額99円

登録で500円分のAmazonギフトカードプレゼント。12月23日まで。※適用条件あり
概要

Luke Laffin, MD, speaks with Steven Nissen, MD, about findings from the ALPACA trial evaluating lepodisiran and its effects on oxidized phospholipids and lipoprotein(a). They discuss the potential mechanisms linking lipoprotein(a) to cardiovascular risk and how ongoing phase 3 research may shape future management of patients with elevated lipoprotein(a).

Looking to refer a patient? Please reach out to our Physician Referral team Mon. - Fri., 8 a.m. - 5 p.m. (ET) at 855.751.2469.

Learn more.

adbl_web_anon_alc_button_suppression_t1
まだレビューはありません